Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study

Charles V. Pollack JrThomas Jefferson University, Philadelphia, PA, USA; Correspondence[email protected]

Richard BernsteinNorthwestern University, Chicago, IL, USA;

Robert DubielBoehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA;

Paul ReillyBoehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA;

Fredrik GruenenfelderBoehringer Ingelheim Corporation, Ingelheim, Germany;

Menno V. HuismanLeiden University Medical Center, Leiden, the Netherlands;

Chak-Wah KamTuen Mun Hospital, Tuen Mun, New Territories, Hong Kong, PR China;

Eva KleineBoehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany;

Jerrold H. LevyDuke University Medical Center, Durham, NC, USA;

Frank W. SellkeRhode Island Hospital, Brown Medical School, Providence, RI, USA;

Thorsten SteinerKlinik für Neurologie, Klinikum Frankfurt Höchst, Frankfurt and Universitätsklinikum, Heidelberg, Germany;

Anastasia UstyugovaBoehringer Ingelheim GmbH, Ingelheim, Germany;

Jeffrey I. WeitzMcMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada

Related Research Data